This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Northwest Biotherapeutics Announces Reverse Split Of Common Stock

BETHESDA, Md., Sept. 26, 2012 /PRNewswire/ -- Northwest Biotherapeutics (NWBO:OTC QB)  (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced that on September 25, 2012 at 5:00 p.m. EDT (the "Effective Date") it effected a one (1) for sixteen (16) reverse split of its issued and outstanding common stock (the "Reverse Split") as a first step in a planned public offering of up to $25 million and listing of its common stock on the NASDAQ Capital Market.


The Company effected the Reverse Split pursuant to an amendment to its Certificate of Incorporation filed with the Secretary of State of Delaware.  In the same filing, the Company also increased the authorized number of shares of preferred stock to 40,000,000 shares.  The Company has no current plans to issue any of the preferred stock.  The foregoing corporate actions were taken via majority consent of the stockholders and all appropriate notifications were filed and transmitted.

Accordingly, as of the Effective Date, each 16 shares of issued and outstanding common stock will be converted into 1 share of common stock.  In addition, the Company's common stock will trade under a new CUSIP number (66737P 600).  The Company's ticker symbol will remain unchanged, although a "D" will be placed on the ticker symbol, NWBO, for 20 business days to alert the public to the Reverse Split. 

 "NW Bio has made strong operational progress in its clinical programs in both the US and Europe, and now is undertaking a major program of strengthening the Company's finances, expanding its resources and raising the Company's market profile," commented Linda Powers, CEO of NW Bio.  "The expanded resources will enable the Company to maintain its momentum in its lead Phase III trial program with DCVax®-L for brain cancer, and accelerate its Phase I/II trial program with DCVax®-Direct for all solid tumor cancers."

The Reverse Split will not change the number of authorized shares of the Company's common stock.  It is not necessary for shareholders of the Company to exchange their existing stock certificates for new stock certificates of the Company in connection with the Reverse Split, although shareholders may do so if they wish to.  Please direct any questions you might have concerning the Reverse Split to your broker or the Company's transfer agent, Computershare, at 866-282-9695.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs